Exane Derivatives’s Sabra Healthcare REIT SBRA Stock Holding History

Exane Derivatives’s Portfolio SBRA Stock Details SBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	-$23	–	730
2018 Q3	$23	Hold	1	–	–	﹤0.01%	672
2018 Q2	$22	Hold	1	–	–	﹤0.01%	664
2018 Q1	$18	Hold	1	–	–	﹤0.01%	611
2017 Q4	$19	Hold	1	–	–	﹤0.01%	596
2017 Q3	$22	Buy	+1	New	+$23	﹤0.01%	557

Other funds holding SBRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AAMU

APG Asset Management US New York $13B AUM 5.3% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Exane Derivatives's SBRA Position: Q4 2018 in Review

Exane Derivatives sold out of Sabra Healthcare REIT (SBRA) in Q4 2018, closing a stake of 1 share — an estimated $23 sold.

Exane Derivatives first reported a position in SBRA in Q3 2017 and held it in 5 quarters. The position peaked at $23 in Q3 2018. 362 funds tracked by Wall St. Rank hold SBRA as of Q4 2018.

Exane Derivatives reported no remaining Sabra Healthcare REIT position as of Q4 2018 after selling out during the quarter.
Exane Derivatives sold 1 Sabra Healthcare REIT share in Q4 2018, an estimated $23.
Exane Derivatives first reported a position in Sabra Healthcare REIT in Q3 2017 and held it in 5 quarters.
Exane Derivatives's Sabra Healthcare REIT position peaked at $23 in Q3 2018.
362 funds tracked by Wall St. Rank held Sabra Healthcare REIT as of Q4 2018.

Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.